PCSA Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 110712 min ago

@ $2.43

Ausgestellt: 12 Feb 2024 @ 21:26

Rendite: -11.52%

Vorheriges Signal: Feb 6 - 20:26

Vorheriges Signal: Verkaufen

Rendite: 0.00 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 19:38):

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...

Stats
Tagesvolumen	266 182
Durchschnittsvolumen	1.52M
Marktkapitalisierung	6.14M
EPS	$0 ( 2024-04-04 )
Nächstes Ertragsdatum	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.250
ATR14	$0.0180 (0.84%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-01	Young David	Buy	1 675	Common Stock
2024-01-01	Young David	Sell	518	Common Stock
2024-01-01	Young David	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Buy	1 675	Common Stock

INSIDER POWER
80.29
Last 99 transactions
Buy: 3 005 145 \| Sell: 402 801

Volumen Korrelation

Lang: -0.10 (neutral)

Kurz: 0.54 (weak)

Signal:(38.72) Neutral

Processa Pharmaceuticals, Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Processa Pharmaceuticals, Korrelation - Währung/Rohstoff

0.81
( strong )

0.80
( strong )

0.00
( neutral )

0.68
( moderate )

0.45
( neutral )

-0.11
( neutral )

Processa Pharmaceuticals, Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$-222.00 (0.00 %)
EPS:	$-8.48

FY	2023
Umsatz:	$0
Bruttogewinn:	$-222.00 (0.00 %)
EPS:	$-8.48

FY	2022
Umsatz:	$0
Bruttogewinn:	$-27.53M (0.00 %)
EPS:	$-68.10

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.750

Financial Reports:

No articles found.

Processa Pharmaceuticals,

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.